A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2025-03-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114
in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose
expansion).